Bannerbild German Brest Group - Patientinnen

Is breast cancer hereditary?

Breast cancer is hereditary. However, hereditary breast cancer only accounts for around five to ten per cent of patients who contract the disease. In the remaining 90 to 95 per cent of cases, the disease has other causes or develops for no apparent reason.

Genetic alterations as a cause for hereditary breast cancer

Hereditary breast cancer is primarily caused by alterations – mutations – in breast cancer genes such as BRCA1 and BRCA2. The abbreviation BRCA stands for BReast CAncer. Large-scale studies of families with an above-average incidence of breast cancer show that, in addition to these genes, further changes in genetic material are responsible for increasing the risk of breast cancer.

Indications of an increased risk of hereditary breast cancer

The following factors point to an increased familial incidence and a possible increased risk of breast cancer [inclusion criteria specified in the Collaborative Research Project for Familial Breast and Ovarian Cancer (Verbundprojekt Familiärer Brust- und Eierstockkrebs) initiated by the German Cancer Aid Organisation (Deutsche Krebshilfe)]:

  • At least two females in the family (mother, sister, daughter or you yourself) have had breast or ovarian cancer, one of whom was younger than 50 at the time of contracting the disease.
  • One female in the family (mother, sister, daughter or you yourself) has contracted unilateral breast cancer at the age of 30 or younger.
  • One female in the family (mother, sister, daughter or you yourself) has contracted bilateral breast cancer at the age of 40 or younger.
  • One female in the family (mother, sister, daughter or you yourself) has contracted breast or ovarian cancer at some time in the past.
  • A male relative has developed breast cancer at some time in the past.

Counselling centres for familial breast cancer

Women with an increased risk of hereditary breast should seek advice from their doctor. They may need to be referred to a special counselling centre. In Germany, there are several familial breast cancer centres. In addition to offering advice, these centres also carry out genetic testing aimed at detecting any possible changes in the BRCA1 and BRCA2 genes. The addresses and telephone numbers of the centres specialising in familial breast and ovarian cancer can be found under the menu item “Breast cancer centres”.

News

  • 17.08.2017  Effect of BRCA1/2 Status on Response to Neoadjuvant Carboplatin in TNBC

    Our paper on mutations analysis in the Geparsixto TNBC-Arm was discussed at ASCO-News.

    Mehr ...
  • 05.07.2017  PALOMA-3 Results published

    Palbociclib Combined with Fulvestrant in PremenopausalWomen with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results

    Mehr ...
  • 03.02.2017  How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?

    Prof. Loibl and Prof. Denkert discuss "How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?" in the current JCO Editorial.

    Mehr ...
  • GBG Jahrestreffen und AGO Mamma State of the Art

    GBG Jahrestreffen und AGO Mamma State of the Art

    Vom 2. bis 3. März 2017 findet das GBG Jahrestreffen 2017 und am 4. März das AGO Mamma State of the Art-Meeting statt. Weitere Informationen finden Sie hier.

    Mehr ...
  • 31.01.2017  Young Investigator Award

    Young Investigator Award

    Die GBG vergibt einen Reise zum ESMO in Madrid in 2017 für junge Wissenschaftler. Bewerbung ab sofort möglich.

    Mehr ...
  • 08.12.2016  The Lancet - Breast Cancer Series 2016

    The introduction of targeted therapies has profoundly changed the course of some subtypes of breast cancer—but many challenges remain. The Lancet’s 2016 Series on breast cancer discusses the most recent advances in the three most common breast cancer subtypes. The first pair of papers focus on the treatment of advanced oestrogen-receptor-positive and HER2-positive breast cancers, while the third describes how an improved understanding of molecular alterations in the heterogeneous and hard-to-treat triple-negative breast cancer may lead to more refined and more effective therapy. http://www.thelancet.com/series/breast-cancer-2016

    Mehr ...
  • 08.11.2016  Tailored, Dense-Dose Chemotherapy for Early Breast Cancer Does Not Result in Significant Improvement in Recurrence-Free Survival

    Among women with high-risk early breast cancer, the use of tailored dose-dense chemotherapy compared with standard adjuvant chemotherapy did not result in a statistically significant improvement in breast cancer recurrence-free survival, and nonhematologic toxic effects were more frequent in the tailored dose-dense group, according to a study appearing in the November 8 issue of JAMA.

    Mehr ...
  • 11.10.2016  Immunotherapy for breast cancer: what does the future hold - BIG Research in Focus now available for download

    BIG Research in Focus - Issue 5, October 2016

    In this issue introduced by Fabrice André (Institut Gustave Roussy, Villejuif, France), leading researchers exchange their views about the potential role of immunotherapies in breast cancer and our current understanding of the immune response to this disease. In addition, an interview of Prof. Gabriel N. Hortobagyi (The University of Texas MD Anderson Cancer Center, USA) gives insight into the trans-Atlantic efforts aiming to move the field of immunotherapies forward faster. We hope you will enjoy the reading.

    Mehr ...
  • 01.08.2016  GAIN 2 – Amendment 3 – neoadjuvanter Behandlungarm ist geöffnet

    GAIN 2 – Amendment 3 – neoadjuvanter Behandlungarm ist geöffnet

    Am 01. August 2016 wurde Amendment 3 der Gain 2 Studie live geschaltet. Es beinhaltet die Öffnung für den neoadjuvanten Behandlungszweig. Zur Erreichung des Rekrutierungsziels (2.886 Patienten) wird die Studie bis QIV 2017 für den Einschluss von Patientinnen geöffnet bleiben.

    Mehr ...
  • 28.07.2016  GBG Annual Meeting 2017 - Save the Date!

    GBG Annual Meeting 2017 - Save the Date!

    Vom 2. bis 3. März 2017 findet in Frankfurt a.M. das GBG Jahrestreffen 2017 statt. Im Anschluss daran findet am 4. März 2017 das AGO Mamma State of the Art Meeting statt. Weitere Informationen finden Sie in unserem Veranstaltungsbereich.

    Mehr ...
  • 14.07.2016  PenelopeB – 50% Rekrutierungsziel erreicht

    PenelopeB – 50% Rekrutierungsziel erreicht

    Am 07. Juli 2016 wurde die 550. Patientin am Krankenhaus Hietzing Wien / Prof. Dr. Sevelda in die PenelopeB Studie randomisiert. Damit wurden 50% der Gesamtrekrutierung erreicht.

    Mehr ...
  • 30.06.2016  INSEMA – 1.000 patients

    INSEMA – 1.000 patients

    Mit Ihrer Hilfe wurde am 30. Juni 2016 die 1.000ste Patientin in die INSEMA-Studie eingeschlossen. Damit ist die geplante Rekrutierungszahl von 5.940 Patienten ein realistisches Ziel. Herzlichen Dank für diese großartige Leistung an alle teilnehmenden Zentren!

    Mehr ...
  • 30.05.2016  Sponsorship award 2015 from the Fritz Acker Foundation

    Sponsorship award 2015 from the Fritz Acker Foundation

    Prof. Dr. med. Sibylle Loibl has won the sponsorship award of the Fritz Acker Foundation in recognition of her research work in the field of oncology.

    Mehr ...
  • 31.03.2016  Guidelines from the Breast Committee of the Working Group for Gynaecological Oncology (AGO)

    The current guidelines from the AGO Breast Committee are published on the AGO’s website.

    Mehr ...
  • 24.03.2016  Order coupon for Breast Care 2016

    Courtesy of the publishing house Karger Verlag, we have again received an order coupon for the “Breast Care” journal 2016. This order coupon entitles GBG members to request a free sample issue or take out a subscription. The form can be downloaded here.

    Mehr ...
  • 08.03.2016  Annual Meeting of the GBG 2016

    Annual Meeting of the GBG 2016

    With over 500 participants, the Annual Meeting was a resounding success. The presentations given on 3 and 4 March will be published in our event archive shortly. Please save the date of the GBG’s next annual meeting: 2 – 3 March 2017.

    Mehr ...
  • 03.03.2016  Relaunch of the website

    All good things take time: the new GBG website has been online since 3 March 2016. We would be pleased to receive your feedback on the new website via the contact form.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd